- Invest in an early-stage companies specializing in biotech therapeutics in the UK. We have made investments in several promising companies from the fund. These include Alevin Therapeutics, CardiaTec, Five Alarm Bio, and others.
- Aiming to build a diverse portfolio with capital growth opportunities and various SEIS tax reliefs. The minimum investment amount for investors is £10k.
- The biotech research sector is one of the leading sectors in the UK economy. The large pharma companies now rely on the small innovative biotech’s for new ideas in disease areas such as cancer and neurosciences, among others, which has led to higher potential exit valuations.
- The team and the advisors operating o2h ventures have been active in grassroots science for over 20 years in the UK.
Fund Status | Open, Closing on 30th June 2024 |
---|---|
Fund Size | Target £10m |
Current AUM | £ 1.1m |
Manager AUM | £ 8.05 million |
Minimum Subscription | £ 10,000 |
Maximum Subscription | £ 200,000 |
Expected Exit | 3-7 years |
Founder's Investment | Minimum 10% of every investment |
Income Tax Relief | Up to 50% of money invested* |
Other Reliefs | Inheritance Tax Relief, Capital Gains Tax Relief, Loss Relief and others |
SEIS tax relief is very attractive for UK tax payers
You invest £50k
SEIS gives you £25k tax relief from HMRC
SEIS gives you £25k tax relief from HMRC
Investment now worth £100k
£50k profit
income tax relief £25k
performance incentive £10k
net profit £65k
Investment still worth £50k
£0 profit
income tax relief £25k
performance incentive £0
net profit £25k
Investment now worth £0
£50k loss
income tax relief £25k
loss relief £15,750 *
performance incentive £0
capital loss £9,250
* Loss relief calculated on higher rate tax bracket Worked example is net of any fund fees
*Tax relief depends on an individual’s circumstances and may change in the future.
- +History in grassroots science
We have a track record of nurturing and investing in emerging life science and tech companies – the o2h ventures team are leaders in the biotech community and have been involved as investors, holding various board/industry positions awe well as being engaged in grassroot scientific activity for over 20 years.
- +Evaluation
- +Access to scientific talents
- +Business model
our portfolio
Sorry, no results found with this search
- o2h Ventures Invests in Stratosvir – Advancing Viral Immunotherapy For Late-Stage Cancer 17 April, 2024
- o2h Ventures Announces SEIS Investment in Innovative mRNA-Based Hearing Loss Treatment Company, CamGene Therapeutics 5 April, 2024
- Pioneering innovation in biotech investments via o2h Ventures’ human health S/EIS funds 20 February, 2024